Citius Pharmaceuticals Inc (CTXR) Unusual Options Activity Today

Checking CTXR unusual options activity helps you spot when traders are making outsized bets on Citius Pharmaceuticals Inc before the broader market catches on. Citius Pharmaceuticals Inc's unusual options activity flags contracts trading at multiples of their average daily volume, often signaling that informed money is positioning ahead of a catalyst. Use our scanner to monitor CTXR unusual options activity today and surface the prints that deserve a second look.

Unusual options flow typically refers to trades where volume vastly exceeds open interest at a given strike, or where total contract volume on a name spikes well above its norm. Watching CTXR unusual options flow today can reveal large block trades, sweeps across exchanges, and aggressive directional bets. Tracking CTXR unusual options volume across calls and puts helps you separate hedging activity from genuinely speculative positioning, and CTXR unusual options flow data becomes especially valuable around earnings, product launches, and macro events.

Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome; and I/ONTAK, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma.

Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.

Catalysts rarely arrive without a footprint, and CTXR unusual options activity is often where that footprint shows up first. Our scanner tracks Citius Pharmaceuticals Inc's unusual options flow in real time, ranks prints by volume-to-open-interest, premium spent, and aggressor side, and separates real conviction from noise. Whether you're looking at CTXR unusual options volume on the call side or chasing put sweeps, Citius Pharmaceuticals Inc's unusual options flow today is one click away, so put it on your radar before the headlines hit.